Answers are grounded in this paper and cite their sources.
Case report demonstrates effective use of rituximab in a patient with refractory warm autoimmune haemolytic anaemia, suggesting alternative management strategies.
This article describes a case of warm autoimmune haemolytic anaemia (w-AIHA) in a 16-month-old refractory to first-line treatment. W-AIHA typically responds to systemic corticosteroids. Here, management proved challenging with re-emergence of haemolysis during initial steroid course. Rituximab offered a turning point, demonstrating the utility of targeted anti-CD20 antibody therapy in achieving a sustained haematological response. The patient’s clinical course was not without further complications potentially attributable to treatments administered. This paper reviews the management of w-AIHA, beyond steroid therapy, with an additional focus on supportive care measures.
No takes yet. Share an insight, caveat, or question.
Clifton et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: